Format

Send to

Choose Destination
Trends Cancer. 2016 Jun;2(6):313-324. doi: 10.1016/j.trecan.2016.05.001.

CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery.

Author information

1
Laboratory of Cancer Biology and Genomics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20814, USA.

Abstract

Advances in translational research are often driven by new technologies. The advent of microarrays, next-generation sequencing, proteomics and RNA interference (RNAi) have led to breakthroughs in our understanding of the mechanisms of cancer and the discovery of new cancer drug targets. The discovery of the bacterial clustered regularly interspaced palindromic repeat (CRISPR) system and its subsequent adaptation as a tool for mammalian genome engineering has opened up new avenues for functional genomics studies. This review will focus on the utility of CRISPR in the context of cancer drug target discovery.

PMID:
28603775
PMCID:
PMC5461962
DOI:
10.1016/j.trecan.2016.05.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center